RJA
MRKR icon

Raymond James & Associates’s Marker Therapeutics MRKR Stock Holding History

Raymond James & Associates’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,400
Closed -$25K – 3994
2022
Q4 		$25K Hold
9,400
– – ﹤0.01% 3776
2022
Q3 		$35K Buy
+9,400
New +$34.5K ﹤0.01% 3742

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's MRKR Position: Q1 2023 in Review

Raymond James & Associates sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 9,400 shares — an estimated $25K sold.

Raymond James & Associates first reported a position in MRKR in Q3 2022 and held it in 2 quarters. The position peaked at $35K in Q3 2022. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • Raymond James & Associates reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 9,400 Marker Therapeutics shares in Q1 2023, an estimated $25K.
  • Raymond James & Associates first reported a position in Marker Therapeutics in Q3 2022 and held it in 2 quarters.
  • Raymond James & Associates's Marker Therapeutics position peaked at $35K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.